We use cookies to give you the best experience possible with our website and to improve our communication with you. We consider your selection and will only use the data you have approved us to gather.

These cookies help making a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

These cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. With this information we can constantly improve the experience we offer on our website.

These cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.

  • Home
  • About medac
  • Information for patients
  • Healthcare professionals
  • Products
  • Career opportunities
  • Media
  • Complete package for SARS-CoV-2 testing

    With immediate effect: 3 million proven antibody tests for SARS-CoV-2 and mastermix ready-to-use PCR tests.

    Read more

    NEW: The Pegfilgrastim biosimilar from medac

    Read more


    Our expertise as a pharmaceutical company

    medac is a future-oriented company and has been growing dynamically since fifty years. More than 1800 medac employees work on the first-time development and further refinement of pharmaceuticals and medical products for the diagnosis and treatment of oncological, urological and auto-immune diseases. Especially when it is a question of niche products we are one of the leading pharmaceutical companies. We represent solid values and basically think in human terms. This results in long-lasting business partnership relations with clinics, doctors and laboratories, as well as providing a healthy working atmosphere for all our employees




    medac statement on Coronavirus (SARS-CoV-2)

    At this moment in time, and after consultation of the competent authorities, we do not foresee any interruptions in production and therefore no supply...

    Trecondi® - the new original from medac

    After 20 years of intensive research and development activity in the field of haematology and oncology, medac received EU-wide marketing authorisation...

    Delivery failure urokinase

    Urokinase medac is not available at the moment. At present, work is underway on a new production of the drug in order to provide patients with...

    Medac at the EBMT 2019

    Innovative conditioning therapy for MDS and AML

    Warning of the off-label use of BCG-medac for the prevention (vaccination) or treatment of COVID-19

    The experimental use of BCG-medac as a vaccine against COVID-19 is associated with a high risk of serious adverse reactions and should therefore be strictly avoided. The Federal Institute for Vaccines and Biomedical Medicines (Paul-Ehrlich Institut (PEI)) has published a respective safety information:


    No news available.
    Nach oben